AbbVie Inc

AbbVie Inc. sees its stock rise 3% after securing a significant licensing deal with Glenmark Pharmaceuticals, while also expanding its portfolio in psychedelic medicine through various collaborations and investments.

AbbVie Inc. has announced a dividend increase, regulatory approval for its ovarian cancer treatment Elahere, and recognition as one of the best workplaces in Asia, among other developments that signal the company’s continued growth and innovation.

AbbVie continues to drive innovation and expansion in the pharmaceutical industry, with recent approvals and acquisitions solidifying its position as a leader in the market.

AbbVie has made a $1.2 billion deal to acquire a depression treatment from Gilgamesh Pharmaceuticals, marking its entry into the psychedelic-based depression drug market.

AbbVie has made a $2.1 billion acquisition of Capstan Therapeutics, positioning itself to lead in cancer research and treatment with cutting-edge tools and technologies.

AbbVie’s acquisition of Capstan Therapeutics has driven record revenue and a significant surge in stock price, positioning the company for long-term success in the autoimmune disease treatment market.

AbbVie Inc has completed its acquisition of Capstan Therapeutics, expanding its immunology pipeline with a potential first-in-class therapy for autoimmune diseases.

AbbVie Inc. has reported strong Q2 earnings, with its stock price more than doubling from its 52-week low and the company raising its 2025 outlook.

AbbVie Inc. has reported strong quarterly earnings, driven by the success of its flagship products Skyrizi and Rinvoq, sending its stock price surging.

AbbVie Inc is in talks to acquire Gilgamesh Pharmaceuticals for approximately $1 billion to enhance its mental health product pipeline.